Cerus reports Phase III Intercept data

CERS and partner Baxter (BAX) said that in an open-label Phase IIIa study of CERS's Intercept Plasma System, 34 patients with hereditary blood clotting factor deficiencies receiving Intercept-treated plasma had increased blood clotting factor levels consistent with historical controls of non-pathogen inactivated plasma. CERS said that Intercept plasma was comparable to historical controls in stopping or preventing bleeding in patients requiring invasive procedures. According to CERS, the study was not statistically powered. ...